A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
Clinical trial NCT05104905 · WITHDRAWN
Trial details
- NCT number
- NCT05104905
- Sponsor
- Faron Pharmaceuticals Ltd
- Status
- WITHDRAWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-07
- Primary completion
- 2022-01-28
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.